GPP
MRSN

Great Point Partners’s Mersana Therapeutics MRSN Stock Holding History

Great Point Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,800
Closed -$230K – 50
2023
Q2 		$230K Buy
+2,800
New +$410K 0.05% 39

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Great Point Partners's MRSN Position: Q1 2021 in Review

Great Point Partners sold out of Mersana Therapeutics (MRSN) in Q1 2021, closing a stake of 19,498 shares — an estimated $13M sold.

Great Point Partners first reported a position in MRSN in Q4 2020 and held it in 1 quarter. The position peaked at $13M in Q4 2020. 132 funds tracked by Wall St. Rank hold MRSN as of Q1 2021.

  • Great Point Partners reported no remaining Mersana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Great Point Partners sold 19,498 Mersana Therapeutics shares in Q1 2021, an estimated $13M.
  • Great Point Partners first reported a position in Mersana Therapeutics in Q4 2020 and held it in 1 quarter.
  • Great Point Partners's Mersana Therapeutics position peaked at $13M in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2021.

Based on Great Point Partners's 13F filing for Q1 2021, filed 17 May 2021.